{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:56:51Z","timestamp":1793858211472,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02938-4","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:02:47Z","timestamp":1788217367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-line anlotinib versus bevacizumab plus CapeOX in RAS\/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Yue","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-9553","authenticated-orcid":false,"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-3717","authenticated-orcid":false,"given":"Kefeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the ANCHOR Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2938_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2938_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes, A. et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 10\u201332 (2023).","journal-title":"Ann. Oncol."},{"key":"2938_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller, L. H. & Schrag, D. Diagnosis and treatment of metastatic colorectal cancer: A review. JAMA 325, 669\u2013685 (2021).","journal-title":"JAMA"},{"key":"2938_CR4","first-page":"372","volume":"72","author":"F Ciardiello","year":"2022","unstructured":"Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J. Clin. 72, 372\u2013401 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"2938_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2938_CR6","unstructured":"National Comprehensive Cancer Network. Colon Cancer, Version 1.2026, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed March 5, 2026 (2026)."},{"key":"2938_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","volume":"124","author":"V Heinemann","year":"2021","unstructured":"Heinemann, V. et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br. J. Cancer 124, 587\u2013594 (2021).","journal-title":"Br. J. Cancer"},{"key":"2938_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe, J. et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: A randomized clinical trial. JAMA 329, 1271\u20131282 (2023).","journal-title":"JAMA"},{"key":"2938_CR9","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","volume":"34","author":"AP Venook","year":"2016","unstructured":"Venook, A. P. et al. Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB\/SWOG 80405 (Alliance). J. Clin. Oncol. 34, 3504\u20133504 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2938_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 19, 329\u2013359 (2021).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"2938_CR11","unstructured":"National Comprehensive Cancer Network. Colon Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.aecp-es.org\/images\/site\/recursos\/documentos\/NCCN_Clinical_Practice_Guidelines_in_Oncology._Colon_Cancer_2019.pdf. Accessed May 15, 2019 (2019)."},{"key":"2938_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin, S. et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J. Hematol. Oncol. 12, 27 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2938_CR13","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","volume":"17","author":"C Lieu","year":"2011","unstructured":"Lieu, C., Heymach, J., Overman, M., Tran, H. & Kopetz, S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res 17, 6130\u20136139 (2011).","journal-title":"Clin. Cancer Res"},{"key":"2938_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao, Y., Langer, R. & Ferrara, N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat. Rev. Drug Discov. 22, 476\u2013495 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2938_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40262-015-0302-2","volume":"55","author":"B Wulkersdorfer","year":"2016","unstructured":"Wulkersdorfer, B., Zeitlinger, M. & Schmid, M. Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. Clin. Pharmacokinet. 55, 47\u201377 (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"2938_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1517\/13543784.2012.689287","volume":"21","author":"T Troiani","year":"2012","unstructured":"Troiani, T. et al. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. Expert Opin. Investig. Drugs 21, 949\u2013959 (2012).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2938_CR17","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1200\/JCO.2012.42.6031","volume":"30","author":"PM Hoff","year":"2012","unstructured":"Hoff, P. M. et al. Cediranib plus FOLFOX\/CAPOX versus placebo plus FOLFOX\/CAPOX in patients with previously untreated metastatic colorectal cancer: A randomized, double-blind, phase III study (HORIZON II). J. Clin. Oncol. 30, 3596\u20133603 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2938_CR18","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/JCO.2012.45.1930","volume":"31","author":"A Carrato","year":"2013","unstructured":"Carrato, A. et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase III trial. J. Clin. Oncol. 31, 1341\u20131347 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2938_CR19","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","volume":"29","author":"JR Hecht","year":"2011","unstructured":"Hecht, J. R. et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J. Clin. Oncol. 29, 1997\u20132003 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2938_CR20","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1200\/JCO.2012.42.5355","volume":"30","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll, H. J. et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III). J. Clin. Oncol. 30, 3588\u20133595 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2938_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed, Y. Y. Anlotinib: first global approval. Drugs 78, 1057\u20131062 (2018).","journal-title":"Drugs"},{"key":"2938_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen, G. et al. Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 11, 120 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2938_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","volume":"125","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled Phase 2 study. Br. J. Cancer 125, 366\u2013371 (2021).","journal-title":"Br. J. Cancer"},{"key":"2938_CR24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han, B. et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4, 1569\u20131575 (2018).","journal-title":"JAMA Oncol."},{"key":"2938_CR25","doi-asserted-by":"publisher","first-page":"e22518","DOI":"10.1200\/JCO.2019.37.15_suppl.e22518","volume":"37","author":"L Tang","year":"2019","unstructured":"Tang, L. et al. Efficacy and safety of anlotinib in advanced soft tissue sarcoma: results from one of multi-centers in a phase IIB trial (ALTER0203). J. Clin. Oncol. 37, e22518 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2938_CR26","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","volume":"27","author":"D Li","year":"2021","unstructured":"Li, D. et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: A randomized, double-blind phase IIB trial. Clin. Cancer Res. 27, 3567\u20133575 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2938_CR27","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-22-3406","volume":"29","author":"Y Chi","year":"2023","unstructured":"Chi, Y. et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II Trial. Clin. Cancer Res. 29, 4047\u20134056 (2023).","journal-title":"Clin. Cancer Res"},{"key":"2938_CR28","doi-asserted-by":"publisher","first-page":"11501","DOI":"10.1200\/JCO.2025.43.16_suppl.11501","volume":"43","author":"Y Zhou","year":"2025","unstructured":"Zhou, Y. et al. Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study. J. Clin. Oncol. 43, 11501\u201311501 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2938_CR29","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","volume":"30","author":"Y Cheng","year":"2024","unstructured":"Cheng, Y. et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat. Med. 30, 2967\u20132976 (2024).","journal-title":"Nat. Med."},{"key":"2938_CR30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1470-2045(25)00343-2","volume":"26","author":"A Zhou","year":"2025","unstructured":"Zhou, A. et al. First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 26, 1145\u20131157 (2025).","journal-title":"Lancet Oncol."},{"key":"2938_CR31","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","volume":"26","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): A randomised, controlled, phase 3 trial. Lancet Oncol. 26, 719\u2013731 (2025).","journal-title":"Lancet Oncol."},{"key":"2938_CR32","first-page":"A6","volume":"34","author":"X Wu","year":"2024","unstructured":"Wu, X. et al. LB011\/#1557 Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: Updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08. Int J. Gynecol. Cancer 34, A6 (2024).","journal-title":"Int J. Gynecol. Cancer"},{"key":"2938_CR33","doi-asserted-by":"publisher","first-page":"e1693","DOI":"10.1002\/onco.13857","volume":"26","author":"Y Chi","year":"2021","unstructured":"Chi, Y. et al. Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo-controlled, randomized phase III trial (ALTER0703). Oncologist 26, e1693\u2013e1703 (2021).","journal-title":"Oncologist"},{"key":"2938_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02357-6","volume":"20","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS\/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Med. 20, 155 (2022).","journal-title":"BMC Med."},{"key":"2938_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1200\/JCO.2024.42.3_suppl.131","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS\/BRAF wild-type unresectable metastatic colorectal cancer. J. Clin. Oncol. 42, 131\u2013131 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2938_CR36","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook, A. P. et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: A randomized clinical trial. JAMA 317, 2392\u20132401 (2017).","journal-title":"JAMA"},{"key":"2938_CR37","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/annonc\/mdx322","volume":"28","author":"KKH Goey","year":"2017","unstructured":"Goey, K. K. H. et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: Updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann. Oncol. 28, 2128\u20132134 (2017).","journal-title":"Ann. Oncol."},{"key":"2938_CR38","doi-asserted-by":"crossref","unstructured":"Stahler, A. et al. Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial. eClinicalMedicine 79, 103004 (2024).","DOI":"10.1016\/j.eclinm.2024.103004"},{"key":"2938_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114036","volume":"205","author":"A Takashima","year":"2024","unstructured":"Takashima, A. et al. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. Eur. J. Cancer 205, 114036 (2024).","journal-title":"Eur. J. Cancer"},{"key":"2938_CR40","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306\u20131315 (2015).","journal-title":"Lancet Oncol."},{"key":"2938_CR41","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065\u20131075 (2014).","journal-title":"Lancet Oncol."},{"key":"2938_CR42","doi-asserted-by":"crossref","unstructured":"Battaglin, F. et al. Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB\/SWOG 80405 (Alliance). Eur J Cancer 227, 115694 (2025).","DOI":"10.1016\/j.ejca.2025.115694"},{"key":"2938_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113374","volume":"195","author":"S Notarnicola","year":"2023","unstructured":"Notarnicola, S. et al. Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments. Eur. J. Cancer 195, 113374 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2938_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103654","volume":"9","author":"C Paratore","year":"2024","unstructured":"Paratore, C. et al. Association between health-related quality-of-life results, outcomes of efficacy and drug approvals: A meta-research study of randomized phase III trials in oncology. ESMO Open 9, 103654 (2024).","journal-title":"ESMO Open"},{"key":"2938_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231152350","volume":"22","author":"J He","year":"2023","unstructured":"He, J. et al. A randomized phase III study of anlotinib versus bevacizumab in combination with CAPEOX as first-line therapy for RAS\/BRAF wild-type metastatic colorectal cancer: A clinical trial protocol. Technol. Cancer Res. Treat. 22, 15330338231152350 (2023).","journal-title":"Technol. Cancer Res. Treat."},{"key":"2938_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.critrevonc.2018.03.003","volume":"125","author":"D Ciliberto","year":"2018","unstructured":"Ciliberto, D. et al. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. Crit. Rev. Oncol. Hematol. 125, 69\u201377 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02938-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02938-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02938-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:02:49Z","timestamp":1788217369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02938-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2938"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02938-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"357"}}